Ugur Sahin, BioNTech CEO

Covid-19 roundup: Pfiz­er-backed BioN­Tech plans to seek FDA OK for a new vac­cine 'as ear­ly as' Oc­to­ber — ahead of the elec­tion

BioN­Tech ex­ecs say they’re on track to get their late-stage da­ta on a Covid-19 vac­cine — part­nered with Pfiz­er — in­to the hands of reg­u­la­tors as ear­ly as Oc­to­ber.

In their Q2 re­lease Tues­day morn­ing, the biotech re­port­ed that in­ves­ti­ga­tors could have late-stage da­ta as ear­ly as Oc­to­ber, and they won’t be wast­ing any time in hus­tling that over to the FDA.

“I am in­cred­i­bly proud of our team, who has worked tire­less­ly to ini­ti­ate our BNT162 Phase 2b/3 tri­al in record time and put us in a po­si­tion to seek reg­u­la­to­ry re­view as ear­ly as Oc­to­ber of this year, if our tri­als are suc­cess­ful,” said Ugur Sahin, BioN­Tech’s CEO and co-founder.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.